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ABSTRACT 
Background
Primary care-based memory clinics (PCMCs) have been 
established in several jurisdictions to improve the care for 
persons with Alzheimer’s disease and related dementias. 
We sought to identify key quality indicators (QIs), quality 
improvement mechanisms, and potential barriers and facili-
tators to the establishment of a quality assurance framework 
for PCMCs.
Methods
We employed a Delphi approach to obtain consensus from 
PCMC clinicians and specialist physicians on QIs and quality 
improvement mechanisms. Thirty-eight candidate QIs and 19 
potential quality improvement mechanisms were presented 
to participants in two rounds of electronic Delphi surveys. 
Written comments were collected and descriptively analyzed.
Results
The response rate for the first and second rounds were 21.3% 
(n = 179) and 12.8% (n = 88), respectively. The majority of 
respondents were physicians. Fourteen QIs remained after 
the consensus process. Ten quality improvement mechanisms 
were selected with those characterized by specialist integra-
tion, such as case discussions and mentorships, being ranked 
highly. Written comments revealed three major themes related 
to potential barriers and facilitators to quality assurance: 1) 
perceived importance, 2) collaboration and role clarity, and 
3) implementation process.
Conclusion
We successfully utilized a consultative process among pri-
mary and specialty providers to identify core QIs and qual-
ity improvement mechanisms for PCMCs. Identified quality 
improvement mechanisms highlight desire for multi-modal 
education. System integration and closer integration between 
PCMCs and specialists were emphasized as essential for the 
provision of high-quality dementia care in community settings.
Key words: quality improvement, primary care, chronic disease 
management, dementia, quality indicators, system integration
INTRODUCTION 
The rising prevalence of Alzheimer’s disease and related 
dementias (henceforth referred to as dementia) is emerging 
as a leading global health system challenge.(1) Effective early 
diagnosis and management models are required to mitigate its 
impact on patients, caregivers, and health-care systems.(2,3) 
Enhancing primary care capacity is seen as essential towards 
achieving this goal.(4-10) However, dementia care predom-
inantly resides with geriatric specialists, who are in short 
supply in Canada and elsewhere, delaying access to care.(11)
To enhance the care of persons with dementia, many com-
munities are creating programs to assess persons presenting 
with cognitive concerns. Many of these have been established 
as primary care-based memory clinics (PCMCs).(4-7,9,10,12,13) 
Initial evaluations suggest that PCMCs can provide timelier 
assessment, lead to a high degree of satisfaction among re-
ferring physicians, patients, and caregivers, and streamline 
access to specialists.(11-13) In order to retain the fidelity of 
such programs and consistency with initial training and 
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practice guidelines, and thus prevent ‘practice drift’ and ensure 
ongoing high quality of care, quality assurance frameworks 
are needed.(9,12,14)
Quality assurance is a process to ensure that care provi-
sion meets established standards.(15) Quality Indicators (QIs), 
based on best practices, define achievable benchmarks and a 
quality assurance framework facilitates practice improvement 
through targeted, educational quality improvement mecha-
nisms.(16,17) To our knowledge, there is no quality assurance 
framework specific to dementia care in primary care-based 
settings. This paper describes the results of a consensus ap-
proach to identify QIs and quality improvement mechanisms 
in an Ontario-wide network of interprofessional PCMCs, and 
identify potential barriers and facilitators to the implementa-
tion of a quality assurance framework.(11,12,18)
METHODS
Protocol and Process
A Delphi technique was deployed to obtain agreement from 
PCMC clinicians and dementia specialists on preferred QIs 
and quality improvement mechanisms.(19-23) The Delphi 
technique is an iterative consensus process, wherein surveys 
are used to solicit opinions from groups, and responses sum-
marized and redistributed in a subsequent round for consider-
ation. We identified 38 candidate QIs and quality improvement 
mechanisms for dementia care by reviewing existing clinical 
guidelines and quality indicator and improvement compendi-
ums developed with standardized methods (Table 1).(16,24-33, 
34) Respondents were asked to rate the QIs and quality im-
provement mechanisms using a continuous integer 9-point 
scale, with 1 representing the least important and 9 the most 
important. Written comments were solicited and professional 
information collected to characterize respondents.
Data Collection
Links to the web-based survey were electronically distribut-
ed to all PCMC clinicians (n = 283) and Ontario specialists 
through the Ontario Medical Association sections of geriatric 
medicine (n = 123) and neurologists (n = 134), and the Ca-
nadian Association of Geriatric Psychiatrists (n = 305). Two 
reminders to complete the survey were sent by e-mail. After 
each round, QIs and improvement measures in the lower 
two tertiles of agreement (i.e., with mean ratings less than 
7) were excluded, and those remaining were reviewed by the 
authors guided by respondent comments.(35) QIs and quality 
improvement mechanisms deemed redundant or containing 
duplicate themes were combined or amended with attention 
to preserving their intent and conciseness. The authors 
maintained an audit trail of changes and decision-making 
points. Data from the preceding round, including number 
of respondents, rating means, and standard deviations, were 
included in the subsequent round.
Data Analysis
Descriptive statistics were compiled after each round. 
Student’s t-test was used to identify significant differences 
between PCMC clinicians and specialists. SPSS version 23.0 
(IBM Corp.) was used, with two-sided p values of < .05 as the 
threshold for statistical significance. Two authors (GH, VB) 
independently analyzed all written comments using descrip-
tive content analysis(36) and incorporated the feedback into 
the presentation of QIs and quality improvement mechanisms 
in the second Delphi round.
RESULTS 
Two survey rounds were conducted between April and June 
2014. In the first Round, 842 surveys were distributed with 
a response rate of 21.3%. The majority of respondents were 
physicians, and nurses and other health professionals equally 
represented the remainder of respondents (Table 2). Respon-
dents had an average of 14.6 ± 10.1 years of clinical practice 
with older adults. Among PCMC respondents, 31% were from 
urban centres, 42% rural settings, and 25% from mixed urban/
rural populations. In contrast, 73% of specialists worked in 
urban settings, and 24% served mixed populations. Only 11 
neurologists responded to the first survey, and their specialty 
was not included in Round 2. 
In Round 2, 690 surveys were distributed with a response 
rate of 12.8%. The majority of respondents (60.2%) were 
physicians. Respondents had an average of 17.42 ± 10.08 
years of clinical practice with older adults and practice set-
tings were similar to Round 1. Respondent characteristics are 
shown in Table 2.
Of the initial 38 candidate QIs, only 14 remained after 
two Delphi rounds. A third Delphi round was not conduct-
ed due to the substantial drop in response rate between 
Rounds 1 and 2. Table 3 presents the results of the con-
sensus process and Table 4 presents the final list of quality 
indicators. Of 19 candidate quality improvement mecha-
nisms, 10 were ultimately selected. Quality improvement 
mechanisms characterized by specialist integration, 
including case discussions, shared care, observerships, 
and mentorships, ranked highly (Table 5). Other preferred 
quality improvement mechanisms included standardized 
electronic charting forms, self-directed learning activities, 
and interactive programs. Survey respondents recommend-
ed that between 10–30% of patients seen in a PCMC also 
be reviewed by a specialist.
Respondent Comments
Descriptive content analysis identified three themes related 
to potential barriers and facilitators to the establishment of 
a quality assurance framework in PCMCs: 1) its perceived 
importance, 2) collaboration and role clarity, and 3) the im-
plementation process.(36) 
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1.  Need for and Relevance of Quality Assurance for 
Dementia Care
Almost all respondents mentioned the need to maintain 
high-quality care through ongoing, targeted training on per-
tinent clinical knowledge and consistency of approach among 
PCMC teams. Most recognized a formal quality assurance 
framework and individual QIs as essential. 
“Great indicators and very necessary” [PCMC cli-
nician, Round 1].
“Our challenge is to maintain evidence based sa-
lience, which ultimately facilitates improved quality 
of life for persons with dementia and their family” 
[PCMC clinician, Delphi Round 2].
“All are relevant quality indicators for a PCMC” 
[Specialist, Round 2]. 
However, a few respondents were unsure why a quality 
assurance framework was needed at all. Some assumed that 
formal training should be sufficient to ensure quality. Others 
seemed unfamiliar with the purpose of quality assurance and 
construed the idea of tracking QIs as supplemental work.
“Is the intent of the questions to assess what we are 
doing now or [what] we think should be the standard?” 
[PCMC clinician, Round 1].
“This is the Canadian Consensus Guideline that ev-
ery doc should know” [Specialist, Round 1; emphasis 
added by authors].
2. Collaboration and Role Clarity
A second theme pertained to the operationalization and 
implementation of the quality assurance framework within 
the context of PCMCs, and identified a lack of clearly delin-
eated responsibilities among referring clinicians, PCMCs, 
and specialists. Respondents perceived this as problematic 
because absence of clarity impedes the capture of clinical 
documentation relevant to QI measurement. 
“Not clear on the team role with caregiver and pa-
tient care plan. Information is sent back to referral 
physician with recommendations for caregiver and 
patient mostly related to change in medication or 
treatment, lifestyle modification and support re-
sources” [PCMC clinician, Round 2].
This lack of clarity was considered most problematic 
with regard to patient follow-up.
“Patients with dementia with great plans should not 
need constant surveillance and follow up BUT... This 
is not my experience... they appear to often benefit 
from a watchdog team to ensure their decisions are 
being carried out.” [Specialist, Round 1].
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Similar concerns were raised regarding the management 
of comorbidities.
“… [My] assumption is that management of co-
morbidities is the primary care physician’s domain. 
Recommendations are made for lifestyle changes, 
however [congestive heart failure] and diabetes 
management are only commented on, suggestions 
are made to the referring physician” [PCMC clini-
cian, Round 2].
It was not clear which health care provider should conduct 
a physical examination, leading to gaps in assessment.
“Referring Family Physicians are expected to have 
completed a complete physical including appropri-
ate neuro exam prior to referral” [PCMC clinician, 
Round 1].
“My biggest concern is that the PCMC team assumes 
that a proper physical and neurologic exam has been 
done by the referring source” [Specialist, Round 1].
3.  Process of QA Framework Implementation  
in PCMCs 
Respondents provided several comments on potential barriers 
to the implementation process of a quality assurance frame-
work in PCMCs. One of the main obstacles was the perceived 
burden of documentation required to implement QIs. 
“[It will take a lot of work to do the] searching and 
documenting as a group of patients needs a process to 
set up how to search, then doing the search” [PCMC 
clinician, Round 2]. 
Integrating QIs into existing electronic medical records 
was touted as a solution, though potentially a resource- 
intensive one.
“Searches are limited by consistency of nomencla-
ture in the chart. Making up stamps to collect this 
information is doable but takes time for someone to 
make the [standardized template] and then to test it” 
[PCMC clinician, Round 2].
TABLE 2.  
Respondent characteristics for both Delphi rounds
Disciplines Round 1 (N = 179): % (n) Round 2 (N = 88): % (n)
Physicians
• PCMC
• Geriatrician
• Geriatric Psychiatrist
• Neurologist
63.1% (112)
25.0% (28)
34.8% (39)
30.4% (34)
9.5% (11)
60.2% (53)
35.8% (19)
34.0% (18)
30.2% (16)
Not applicablea
Nursing (RN, R/LPN, NP) 16.2% (29) 15.9% (14)
Allied Health Professionals 16.2% (29) 20.5% (18)
Other 5.0% (9) 3.4% (3)
Practice settings (%) PCMC Clinicians
(N = 95)
Specialists
(N = 84)
PCMC Clinicians
(N = 54)
Specialists
(N = 34)
Urban 30.5 (29) 72.6 (61) 24.1 (13) 44.3 (26)
Rural/remote 42.1 (40) 2.4 (2) 40.7 (22)  2.9 (1)
Mixed urban/rural 25.3 (24) 23.8 (20) 35.2 (19)  20.6 (7)
Clinical practice experience PCMC Clinicians
(N = 78)
Specialists
(N = 77)
PCMC Clinicians
(N = 50)
Specialists
(N = 31)
Mean (SD), years 13.09 (10.5) 16.09 (9.4) 15.32 (9.5) 20.81 (10.2)
aRound 2 surveys were not distributed to neurologists.
RN = Registered Nurse; RPN = Registered Practical Nurse; LPN = Licensed Practical Nurse; NP = Nurse Practitioner; Other = Professionals 
from the Alzheimer’s Society and other community support services, physician assistants, and administrators. Allied Health Professionals 
included social workers, occupational therapists, physiotherapists, and pharmacists.
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TABLE 3.  
Summary of Quality Indicator selection process
QI Short Form Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Respondents’ Comments
Process indicators
1. Access time 6.86 (1.95) n/a No Excluded after Round 1 due to rating below 7.
2.
2.1
2.2
2.3
2.4
2.5
Consult note content
7.75 (1.66)
8.11 (1.20)
8.03 (1.28)
7.91 (1.38)
8.15 (1.41)
8.01 (1.08)
8.09 (1.07)
8.12 (1.10)
7.68 (1.43)
7.55 (1.78)
No Excluded after review.
Survey respondent comments raised concerns about how to measure 
this, given the perceived role confusion between referring physicians 
and PCMC clinicians: ‘There may be some confusion between the 
treatment plan and the treatment recommendations left up to the 
referring physician to manage [PCMC clinician, Round 1].
3.
3.1
3.2
3.3
3.4
3.5
3.6
Specialist referrals
7.56 (1.68)
7.81 (1.68)
7.63 (1.81)
7.62 (2.00)
7.26 (2.03)
6.82 (2.00)
7.19 (1.71)
7.11 (1.76)
7.30 (1.69)
7.06 (1.94)
6.84 (2.08)
n/a
Yes Final Quality Indicator (FQI) 1
Sub-item 3.6 excluded after Round 1 due to low rating.
Sub-item 3.5 scored below 7 after Round 2 but was retained, as this 
PCMC model explicitly stipulates that patients younger than 65 with 
suspected dementia will be referred to a specialist.
After review, sub-items 3.1 to 3.5 combined into a single FQI.
4. PCMC activity log 6.40 (1.98) n/a No Excluded after Round 1 due to rating below 7.
5. Client satisfaction 6.98 (1.73) n/a No Excluded after Round 1 due to rating below 7.
6. Referring clinician 
satisfaction
6.94 (1.62) n/a No Excluded after Round 1 due to rating below 7.
Assessment and Reassessment
7.
7.1
7.2
7.3 
7.4
7.5
7.6
7.7
7.8
Charting completeness
7.98 (1.30)
6.79 (1.94)
7.16 (1.89)
8.50 (1.06)
8.17 (1.07)
8.22 (1.00)
8.23 (1.06)
7.72 (1.44)
8.09 (1.27)
n/a
6.71 (1.82)
8.31 (1.12)
7.72 (1.42)
7.96 (1.26)
8.10 (1.30)
7.27 (1.78)
Yes FQI 2 (modified after review)
Sub-item 7.2 (general physical examination) was excluded after 
Round 1 due to rating below 7.
Sub-item 7.3 (screening neurological examination) was excluded 
after Round 2 due to rating below 7. However, there was a statistically 
significant difference between ratings by PCMC clinicians (6.35 
(1.91)) and specialists (7.28 (1.53)); the latter favouring sub-item 7.3.
Sub-item 7.6 had an overall rating over 6.99, but the review excluded 
the sub-item (patient needs in multiple domains) because respondents 
considered it potentially too variable to permit a sufficiently specific 
definition to allow for accurate measurement. One respondent 
commented: “Referral, further testing and reassessment are important 
but should also be based on patient/caregiver complaints and needs” 
[Specialist, Round 1].
Sub-item 7.8 had an overall rating over 6.99, but the review 
(documentation of multidisciplinary discussion) excluded the sub-
item because it is a required process in the PCMC model of care, 
variability exists in the multidisciplinary composition of individual 
teams, and documentation of whether or not a discussion occurred 
does not reflect the quality and content of the discussion and can 
therefore not be easily assessed as a QI: “At our Memory Clinic, 
each patient cannot be followed up in our Memory Clinic annually 
because of limited resources” [PCMC clinician, Round 2].
The remaining sub-items (7.1, 7.4, 7.5, and 7.7) were combined 
into a single QI (FQI 2) of readily measurable clinical diagnostic 
documentation.
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A second issue identified in relation to the implementation 
of the quality assurance framework is the need to establish 
benchmarks to properly interpret QI scores. Respondents 
suggested that specialist involvement with PCMCs could 
help define these benchmarks. However, access to specialists 
within a PCMC was often seen as insufficient.
“I think one of the most important quality indicators 
is a comparison of the PCMC performance versus 
the specialist, done on both patients referred to the 
specialist by the PCMC, and unselected patients seen 
in the clinic that would not have been referred to the 
specialist” [Specialist, Round 1].
Access to other health care professionals, within PCMCs 
and in the community, was identified as important for quality 
care, though access was not perceived as uniform.
TABLE 3.  
Continued
QI Short Form Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Respondents’ Comments
Assessment and Reassessment
8.
8.1
8.2
8.3
8.4
8.5
Diagnostic  
supporting data
7.41 (1.73)
7.49 (1.68)
7.90 (1.46)
7.92 (1.37)
7.87 (1.43)
7.69 (1.37) Yes FQI 3 (modified after review)
Sub-items 8.1 to 8.5 were combined into one QI (FQI 3) after Round 
1 due to general agreement for inclusion (mean ranking = 7.72, range 
7.41–7.92, no significant differences between groups). Furthermore, 
all 5 sub-items reflect important elements of the dementia diagnosis 
and are thus conceptually related.
9. Annual dementia 
severity tracking
7.10 (1.52) n/a No Excluded after Round 1 because this QI was deemed too similar 
to, though less easily defined, than an assessment of functional 
status as an indicator of dementia severity of dementia (QI 12). 
Survey respondents commented: “Not sure how the PCMC could 
accurately determine severity of dementia as mild, moderate or 
severe” [Specialist, Round 2]; “Confusion re: mild, moderate, severe 
dementia....so we don’t use these terms consistently...or really much 
at all” [PCMC clinician, Round 2].
10. MCI 1-year 
reassessment
7.37 (1.62) 7.26 (1.66) Yes FQI 4
11. Dementia 1-year 
cognitive review
7.40 (1.40) 7.42 (1.48) Yes FQI 5 (integrated with QIs 12, 28 and 32 after review as conceptually 
similar).
12. Dementia 1-year 
function review
7.58 (1.39) 7.56 (1.53) Yes FQI 5 (integrated with QIs 11, 28, and 32 after review).
13. Dementia 1-year 
behaviour review
7.39 (1.57) 6.86 (1.84) No Excluded after Round 2 due to rating below 7.
Medication Review and Management
14. Medication review 8.47 (1.01) 8.27 (1.30) Yes FQI 6: integrated after review with QIs 15 to 17 due to substantial 
content overlap. Survey respondents commented: “I think justifying 
every medication that could have cognitive effects and documenting 
this with every patient would be too detailed,” and “Of utmost 
importance is the identification of the medication (prescribed and 
OTC).” [Specialist, Round 2].
15. Medication review and 
justification
8.09 (1.42) 7.82 (1.35) Yes QIs 15 to 17 were combined into one QI after Round 1 due to 
substantial overlap in content. The remaining QI was integrated with 
QI 14 into FQI 6 after review.16. Anticholinergic 
medication review
7.53 (2.01)
17. Sedative medication 
review
7.51 (1.98)
Investigations
18. Lab testing 8.02 (1.35) 7.79 (1.34) Yes FQI 7
19. Neuroimaging 8.13 (1.17) 7.90 (1.33) Yes FQI 8
CANADIAN GERIATRICS JOURNAL, VOLUME 19, ISSUE 4, DECEMBER 2016
HECKMAN: QUALITY ASSURANCE IN COMMUNITY DEMENTIA CARE
173
TABLE 3.  
Continued
QI Short Form Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Respondents’ Comments
Non-Pharmacological Management
20.
20.1
20.2 
20.3 
20.4
Diagnosis discussion
7.93 (1.35)
7.45 (1.45)
7.61 (1.31)
7.24 (1.59)
7.85 (1.18)
7.41 (1.30)
7.70 (1.19)
7.37 (1.36)
No QI and all sub-items were excluded after review. While all sub-items 
ranked above 6.99, several survey respondents expressed concerns 
that the amount of information to be discussed regarding diagnosis 
and implications can only be delivered over several appointments, 
thus making accurate and meaningful measurement of this QI 
difficult: “Patients and their family are often overwhelmed at 
the time of feedback...and would not be able to absorb all this 
information” [PCMC clinician, Round 1]; “The conveyance of 
information could take place over several weeks or months as the 
amount of information mentioned above (and important to convey) 
would be likely to be overwhelming to a patient and family with a 
new dx of dementia. So I think it is important that all above info be 
conveyed, but possibly with proviso that it be within 1–3 months of 
initial diagnosis” [Specialist, Round 2].
21. Individualizing care 
plan
7.82 (1.40) n/a No Excluded after Round 1 review. This QI was considered too 
vague and potentially too variable to permit a sufficiently 
specific definition to allow for accurate measurement. Survey 
respondents commented: “There may be challenges in interpreting 
documentation for some of these factors (i.e. may not be explicit)” 
[PCMC clinician, Round 1].
22. Individualized 
caregiver support
7.66 (1.46) n/a No Excluded after Round 1 review. QI was considered too vague and 
potentially variable to permit a sufficiently specific definition to 
allow for accurate measurement. A PCMC clinician stated: “Care 
plans for caregivers is tricky because they are not necessarily your 
patient and may not share the same family physician as the index 
patient” [PCMC clinician, Round 1].
23. Caregiver education 8.13 (1.28) n/a No Excluded after Round 1 review. Referral to external resources 
for support, particularly the Alzheimer’s Society, is an intrinsic 
aspect of CFFM PCMC clinic processes and staffing. Furthermore, 
documentation of whether the referral is made does not ensure 
that the referral took place and whether or what type of support 
was provided. Survey respondents commented: “This is difficult to 
answer in some ways because it’s asking about the clinic alone. A 
lot of this work is done in collaboration with community partners” 
[PCMC clinician, Round 1].
24 End-of-life planning 7.19 (1.81) 6.52 (1.89) No Excluded after Round 2 due to rating below 7.
25. Advance care plan 7.62 (1.57) 7.28 (1.71) Yes FQI 9
26. System navigation 
information
7.60 (1.62) 7.14 (1.59) No Excluded after review. System navigation services might be 
provided by resources external to PCMCs and therefore are not 
easily measurable or reflective of the care at the PCMC program per 
se. See survey respondent comments to QI 23.
27 Documented capacity 
assessment
7.42 (1.77) 7.10 (1.69) No Excluded after review. Capacity for decision-making is an 
intrinsic component of advanced care planning, addressed by FQI 
9. Furthermore, in practice, this process often involves shared 
care with the specialist, to which referrals are addressed by care 
processes inherent in the PCMC model. Survey respondents raised 
concerns about measurability, as capacity changes over time: 
“Regarding capacity to make decisions - since capacity is decision 
specific - you may not have the opportunity to assess this within a 
12 month period if the need for a specific decision does not arise” 
[Specialist, Round 2].
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“Having a pharmacist on our team is a great asset....
The local [pharmacists] volunteer their time to assist 
us at our once monthly day long clinics” [PCMC 
clinician, Round 2].
“The [Social Work] and [Occupational Therapy] 
members of the team do an excellent job…the 
[Alzheimer’s Society] representative has been ex-
cellent as well when given an opportunity” [PCMC 
clinician, Round 2]. 
An important finding is the relative lack of importance 
ascribed to end-of-life planning. While respondents agreed on 
its importance, many expressed that such planning discussions 
were not appropriate for patients with less advanced disease.
“Palliation and end of life discussion is usually not 
appropriate at time of our memory clinic initial or 
follow-up assessment since our patients are not that 
advanced. Family physician team will do this in 
following up patient” [PCMC clinician, Round 1].
TABLE 3.  
Continued
QI Short Form Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Respondents’ Comments
Non-Pharmacological Management
28. Overall safety risk 
assessment
8.06 (1.38) 8.06 (1.21) Yes FQI 5 but integrated with QIs 11, 12, and 32 after review. This 
QI was then integrated into a single QI relating to 12-month 
reassessment.
29. Overall safety 
counselling
7.45 (1.76) 7.28 (1.51) No Excluded after review due to significant overlap with QI 28.
30. Driving counselling 7.94 (1.52) 8.10 (1.08) Yes Accepted with modification after review (FQI 10). This QI was 
reworded after review to address that this only applies to patients 
that are still able to drive.
31. Driving assessment 7.89 (1.60) 7.61 (1.53) Yes FQ11 was reworded after review to address that this only applies to 
patients that are still able to drive.
32. Behaviour intervention 7.46(1.76) 7.22(1.53) Yes FQI 5 (integrated with QIs 11, 12, and 28 after review). This QI was 
then integrated into a single QI relating to 12-month reassessment.
Pharmacological Management
33. Acetylcholine-esterase 
inhibitor discussion
7.81 (1.46) 7.96 (1.24) Yes FQI 12
34. Documented non-
pharmacological 
behavioural 
intervention
7.41 (1.72) 7.24 (1.76) Yes FQI 13 (combined with QI 35 after review because of substantial 
conceptual overlap. Statistically significant difference with 
specialists favouring this QI more than PCMC clinicians (7.81 
(1.26) vs. 6.85 (1.96), p < .01).
35. Antipsychotic risk 
discussion
7.72 (1.75) 7.57 (1.59) Yes FQI 13 (combined after investigator review with QI 34 because of 
substantial conceptual overlap)
Managing concomitant conditions
36. Nutritional assessment 6.88 (1.73) n/a No Rating below 7 after Round 1.
37. Comorbidity 
management support
7.00 (1.75) 7.13 (1.45) No Excluded after review because of differences between PCMC staff 
and specialist ratings (6.96 (1.43) and 7.13 (1.45)). Several survey 
respondent comments raised concerns about how to measure this 
given role confusion between referring physicians and PCMC. 
Survey respondents commented: ‘The prophylaxis and chronic 
disease care is done by the family doctor.” [PCMC clinician, Round 
1]; “Advice and support on management of complex comorbidities 
should certainly be recommended to the patient’s family doctor, but 
not necessarily within the purview of the PCMC itself.” [Specialist, 
Round 1]; “Managing concomitant conditions is important but 
not always feasible given the complexity of dementia assessment” 
[Specialist, Round 2].
38. Stroke prophylaxis 7.15 (1.69) 7.41 (1.57) Yes FQI 14
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Lastly, many respondents expressed a preference for 
quality improvement mechanisms and learning opportunities 
characterized by active engagement. They also identified 
specialists as agents to promote care quality, particularly in 
the context of a shared care approach. 
“This [case review] could be done at the same time, 
as the specialist mentoring the clinic is in a clinic day 
with the team” [PCMC clinician, Round 1].
TABLE 4. 
Final Quality Indicators (FQIs) and operational definitions
Numerator Denominator
Process Indicators
FQI 1: Patients referred by the PCMC to a specialist if one or more of the following is documented:
1. Course of the dementia is rapidly progressive;
2.  Characteristics suggest rare types of dementia, such as focal or frontal features or visual 
hallucinations in early stages of the dementia; 
3.  Persistent patient or caregiver complaints of problematic symptoms, or unexplained investigation results; 
4. Uncertainty about the diagnosis; and
5. Patient is younger than 65 years.
All patients seen in the PCMC with 
documentation of one or more of 
these 5 indicators.
Assessment and Reassessment Indicators
FQI 2: Proportion of patients seen in PCMC with clinical diagnostic documentation for dementia, 
whereby the documentation includes ALL of the following:
1. “History from other sources” (collateral);
2. Cognitive testing;
3. Assessment of caregiver’s burden and needs; and
4. Mood screening test.
All patients seen in the PCMC.
FQI 3: Proportion of patients seen in PCMC that have a documented diagnosis of dementia that is 
explicitly supported by documentation of ALL of the following criteria:
1. Acquired and a decline from previous function;
2. Affects two or more cognitive domains;
3. Leads to impairment in occupational or social functioning;
4. Negative influence on daily functioning; and
5. Absence of a delirium.
All patients seen in the PCMC and 
who are diagnosed with dementia.
FQI 4: Proportion of patients seen in the PCMC who have a documented diagnosis of Mild 
Cognitive Impairment (MCI) and who are reassessed within 12 months of the initial assessment. 
All patients seen in the PCMC with 
a documented diagnosis of MCI.
FQI 5: Proportion of patients seen in the PCMC who have a documented diagnosis of dementia and 
who are reviewed at least once within a 12-month period to undergo an assessment for:
1. Cognition;
2. Function;
3. Behavioural and neuropsychiatric symptoms; and
4.  Safety concerns (driving, financial management, medication management, home and 
environmental risks, wandering).
All patients seen in the PCMC and 
who are diagnosed with dementia.
Medication Review and Management Indicators
FQI 6: Proportion of patients seen in the PCMC who have a documented diagnosis of dementia or 
MCI, who are taking medications commonly associated with mental status changes, and for whom 
these medications are either:
1. Discontinued, or
2.  Continued but with clearly documented justification outlining why their expected benefits 
outweigh their potential negative impact on cognition.
All patients seen in the PCMC 
diagnosed with dementia or MCI, 
and who are taking medications 
associated with mental status 
changes.
Investigations Indicators
FQI 7: Proportion of patients seen in the PCMC that are assessed for cognitive impairment and in 
whom all recommended blood tests are performed, including: Complete blood count, creatinine, 
serum B12, thyroid stimulating hormone, serum electrolytes, serum calcium, and serum fasting 
glucose.
All patients seen in the PCMC.
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TABLE 4. 
Continued
Numerator Denominator
Process Indicators
FQI 8: Proportion of patients seen in the PCMC that are assessed for CI in whom structural cranial 
imaging is recommended if one or more of the following criteria are present and documented:
1. Age < 60 years;
2. Rapid (e.g., over 1–2 months) unexplained decline in cognition or function;
3. Short duration of dementia (< 2 years);
4. Recent head trauma;
5. Unexplained neurologic symptoms (e.g., new onset of severe headache or seizures);
6. History of cancer (especially types that metastasize to the brain);
7. Use of anticoagulants or history of bleeding disorder;
8.  History of urinary incontinence and gait disorder early in the course of dementia (as may be 
found in normal pressure hydrocephalus);
9. Any new localizing sign (e.g., hemiparesis or a Babinski reflex); 
10. Unusual or atypical cognitive symptoms or presentation (e.g., progressive aphasia); and/or
11. Gait disturbances.
All patients seen in the PCMC 
and in whom one or more of these 
features is documented.
Non-Pharmacological Management Indicators
FQI 9: Proportion of patients seen in the PCMC with a documented diagnosis of dementia for 
whom, within 2 years of initial dementia diagnosis, an advance care plan (e.g., will, enduring 
power of attorney, personal directive) is established and a surrogate decision-maker identified in the 
medical record, unless it is documented in the medical record that the patient did not wish to, or was 
not able to, name a surrogate decision-maker or provide advance care plans.
All patients seen in the PCMC and 
who are diagnosed with dementia.
FQI 10: Proportion of patients seen in PCMC, who have a driver’s license and/or are driving with a 
documented diagnosis of dementia, and/or their caregivers, and who received counselling regarding 
the risks of driving and the alternatives at least once within a 12-month period.
All patients seen in the PCMC, 
diagnosed with dementia, and who 
have a valid driver’s license and/or 
are driving.
FQI 11: Proportion of patients with dementia who have a driver’s license and/or are driving in whom 
driving ability is assessed at least once within a 12-month period.
All patients seen in the PCMC, 
diagnosed with dementia, and who 
have a valid driver’s license and/or 
are driving.
Pharmacological Management Indicators
FQI 12: Proportion of patients seen in the PCMC with a documented diagnosis of mild to moderate 
Alzheimer’s Dementia, mild to moderate vascular dementia, or Lewy body dementia, with whom a 
discussion with the patient and/or caregiver about the risks and benefits of cholinesterase inhibitor 
treatment is documented.
All caregivers and/or patients seen 
in the PCMC with a documented 
diagnosis of mild to moderate 
Alzheimer’s Dementia, mild to 
moderate vascular dementia, or 
Lewy body dementia.
FQI 13: Proportion of patients with dementia and neuropsychiatric symptoms, for whom an 
antipsychotic is prescribed, and for whom a discussion considering non-pharmacological options 
and potential benefits and harms of these medications, had taken place and has been documented in 
the patient’s record.
Patients seen in the PCMC and 
who have been prescribed an 
antipsychotic medication.
Managing Concomitant Conditions Indicators
FQI 14: Proportion of patients as seen in the PCMC with a documented diagnosis of dementia and 
vascular risk factors who are considered for stroke prophylaxis.
All patients referred to the PCMC, 
who have vascular risk factors, 
and who have no documented 
contraindications for stroke 
prophylaxis. The management 
of patients with severe dementia 
(as per Clinical Dementia Rating 
Scale) should be considered on an 
individual basis and fall beyond the 
scope of this QI.
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TABLE 5. 
Ranking of Quality Improvement mechanisms
Mechanism Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Comments From Respondents
Case discussions 7.63 (1.48) 7.72 (1.30) Yes Specialist comments:
•  “I think case reviews with a specialist are a great way to 
train/upgrade/empower a PCMC team to perform better/
more independently over time.” 
•  “…to be honest, I think all PCMCs should review all 
cases with a specialist for at least the first year or two, 
with full consult/review [..], depending on PCMC team 
confidence, on a case by case basis after that.”
•  “Case reviews would be useful but the expectation is 
impractical given the scarcity of geriatric specialist 
resources.”
Mixed didactic/interactive 
  programs: Regular 
conferences for all PCMCs 
(Booster day sessions)
7.5 (1.64) 7.64 (1.24) Yes PCMC clinician comments:
•  “Booster Days are great....and the opportunity to send 
new team members to MC training is vital.”
• “Booster days are extremely useful and recharging.”
Standardized clinical 
 charting forms
7.39 (1.79) 7.51 (1.27) Yes
Clinical observership/ 
 mentorship/shared consults
7.73 (1.43) 7.42 (1.34) Yes PCMC clinician comments:
•  “This could be done at the same time as the specialist 
mentoring the clinic is in a clinic day with the team.”
•  “In a perfect world it would be great to have all assessed 
by specialist.”
Specialist comments:
•  “I think the key parameter here will be a peer assessment 
by a third party.”
Self-directed learning 7.29 (1.73) 7.33 (1.38) Yes
Clinical reasoning  
 models/algorithms
7.28 (1.77) 7.29 (1.44) Yes
On-site case reviews  
 with PCMC team
7.26 (1.78) 7.29 (1.47) Yes
Interactive programs: 
 Communities of Practice, 
 networking, shared  
 experiences, problem-solving
7.15 (1.71) 7.15 (1.60) Yes PCMC clinician comments: “Very interesting to share 
information and discuss about difficult cases but not realistic 
to obtain a network between the clinics. Could be possible 
though within small groups.”
Regular chart audits  
 and feedback
7.02 (1.65) 6.96 (1.59) Yes While the score on the second Delphi round was less than 
7.00, audit and feedback is intrinsic to QA, and therefore it 
was retained.
PCMC clinician comment: “Always open to improving our 
care at memory clinic by having feedback from experts.”
E-learning modules 7.02 (1.78) n/a Yes This mechanism was unintentionally dropped from the 
second Delphi survey. After discussion, a decision was made 
to retain it given the likelihood that ratings would not have 
changed substantially, and taking into consideration the 
comment below.
PCMC clinician comment: “E-learning, DVD, Journal club 
and webinars, written papers etc... would be useful but it 
is being able to fit those into our busy schedules and other 
responsibilities.”
Electronic reminders/cues 7.09 (1.82) 6.73 (1.82) No Rating below 7.00
Distribution of written material 6.72 (1.94) n/a No Rating below 7.00
CANADIAN GERIATRICS JOURNAL, VOLUME 19, ISSUE 4, DECEMBER 2016
HECKMAN: QUALITY ASSURANCE IN COMMUNITY DEMENTIA CARE
178
Overall, respondents recognized the need for a quality 
assurance framework for dementia care. Barriers to the imple-
mentation of this framework included role confusion among 
stakeholders and limited resources. Integrated electronic data 
collection was considered a facilitator for quality assurance. 
DISCUSSION
This study used a consultative process among primary 
and specialty providers to identify a core group of QIs and 
preferred quality improvement mechanisms for dementia 
care. Quality assurance can be an effective method to en-
sure fidelity to best practices and maintain a high standard 
of care quality.(37-41) Selected QIs address care processes, 
assessment and reassessment, medication review and man-
agement, investigations, non-pharmacological management, 
pharmacological management, and managing concomitant 
conditions.(42) Selected quality improvement mechanisms 
emphasize a desire for multimodal education and closer 
collaboration with specialists. Assessing care quality and 
publically reporting the findings are increasingly common-
place. However, quality assurance still mainly focuses on 
specific care sectors or episodes, rather than on overall care 
for conditions that require coordination and collaboration 
across multiple sectors.(43) In that context, study participants 
identified important hurdles to its implementation.
Critical considerations include educating clinicians 
about the role of quality assurance, improving role clarity 
among providers involved in dementia care, expanding 
access to allied health professionals, and creating standard-
ized electronic medical record templates to simplify QI 
documentation. Quality assurance must not create additional 
burden on clinicians often working with limited resources 
and time, a burden that could also impact the quality of the 
clinician-patient interaction. Greater integration of special-
ists within PCMCs was acknowledged as important for care 
quality. Respondents proposed that 10–30% of patients seen 
in PCMCs be reviewed with a specialist, preferably in a 
shared care approach. Closer integration of urban specialists 
with rural PCMCs represents a tremendous opportunity to 
extend quality dementia care, particularly to rural patients. 
However, integration of specialists within PCMCs remains 
suboptimal. To optimize specialist integration, it will be 
necessary to identify barriers (e.g., allocation of funding) 
and facilitators (e.g., resources for coordination, electronic 
medical records, telemedicine). Another important finding 
was the relatively low rankings of QIs related to end-of-life 
planning with dementia patients. In addition to potential dis-
comfort among clinicians to address such issues, this finding 
may also stem from the understandable desire to maintain 
hope and engagement early in the course of the illness, though 
undue delays may leave patients and caregivers less able to 
meaningfully participate in such discussions.
The most important identified barrier to the implementa-
tion of the quality assurance framework is the need for greater 
clarity on responsibilities of referring family physicians, 
PCMC clinicians, and specialists, particularly with respect 
to follow-up, physical examination, and care of complex co-
morbidities. Quality assurance often targets relatively simple 
conditions, such as hypertension, or restricts its scope to spe-
cific aspects, processes or locations of care.(38-41) In contrast, 
dementia, like all major chronic conditions, follows a course 
of progressive decline punctuated by increasingly frequent 
health complications (related to dementia itself, as well as 
to exacerbations of concurrent comorbidities), multiple care 
transitions, progressive caregiver stress and health service 
utilization, and ultimately death. Optimal dementia care thus 
requires a systems approach of integration and coordination.
(44,45) Addressing greater role clarity among all dementia 
stakeholders, a task that with proper resources could be co-
ordinated from within PCMCs,  requires immediate attention, 
in order to ensure a stable clinical infrastructure that is able 
to safely and effectively address the needs of these patients, 
wherever they may be and whenever they arise.(46,47) Until 
TABLE 5. 
Continued
Mechanism Round 1
Mean (SD)
Round 2
Mean (SD)
Accepted? Review Details and Comments From Respondents
Webinars 6.71 (1.66) n/a No Rating below 7.00
Web-based/DVD videos 6.62 (1.96) n/a No Rating below 7.00
Regular Mandated 
 Patient Consultations
6.52 (1.95) n/a No Rating below 7.00
Pocket Cards 6.32 (2.12) n/a No Rating below 7.00
Mobile Apps 6.32 (2.15) n/a No Rating below 7.00
Didactic programs: 
 Lectures/presentations
6.30 (1.95) n/a No Rating below 7.00
Journal clubs 6.25 (1.97) n/a No Rating below 7.00
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such integration is achieved, optimal quality dementia care 
will remain difficult to attain.
Limitations of the Study
The results of this study should be understood in light of 
several limitations. First, only two Delphi rounds were 
conducted because the response rate fell markedly after the 
first. However, the response rate remained above what is 
considered appropriate for Delphi surveys, and ratings of 
individual QIs, except those related to physical examination, 
remained stable between rounds.(48,49) A second limitation is 
that the survey was solely distributed within the previously 
described network of PCMCs,(11-13) though this model is 
widely implemented across Ontario. As the QIs were selected 
by both primary and specialist providers, they are likely ap-
plicable to other dementia care settings. Third, participation 
of neurologists in the first round was low and their response 
was not solicited in the second round. The relatively lower 
participation of neurologists in this work, compared to ger-
iatricians and geriatric psychiatrists, is notable and requires 
further investigation. Fourth, allied health providers were 
under-represented and, given their importance in dementia 
care, additional work is required to further understand and 
develop their role in an integrated system of dementia care. 
Fifth, patient and caregivers were not surveyed regarding what 
they consider to be important QIs. Finally, candidate QIs and 
quality improvement mechanisms were not identified through 
a systematic literature review, but the use of published guide-
lines and compendiums likely identified the most important 
elements of quality dementia care, which would thus have 
remained highly ranked.
CONCLUSIONS
While this study has identified QIs and quality improvement 
mechanisms to assess care quality for dementia, findings 
underscore the importance of system integration for the pro-
vision of quality dementia care, with specifically defined and 
mutually understood roles among stakeholders and, where 
necessary, the reallocation of existing resources to support this 
approach to care.(50) Understanding and overcoming system 
barriers to dementia care integration is an urgent priority. An 
approach whereby clear roles are negotiated among dementia 
stakeholders can provide sufficient flexibility to meet regional 
needs (especially in rural areas where access to specialists 
is more limited), foster more effective collaboration and 
accountability, and thus facilitate the delivery and measure-
ment of care quality for dementia. Within that context, proper 
field-testing, validation, and evaluation of selected QIs and 
quality improvement mechanisms can then be conducted. 
This work has significant implications on the organization 
of care for aging patients with complex conditions. Primary 
and specialist providers share the responsibility of providing 
and supporting integrated dementia quality care. As such, 
the care of persons with cognitive impairment would be 
enhanced by the development of a practical and realistically 
feasible quality assurance framework, under whose umbrella 
both PCMC and specialist services are integrated, and which 
ensures high fidelity to intended design and best practices, 
and thus maintains a high level of care quality.(51)
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